Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2005
03/10/2005US20050054629 Antiproliferative agents; anticancer agents; restenosis
03/10/2005US20050054623 Transdermal supplying testosterone gel
03/10/2005US20050054619 Suppression tumor growth
03/10/2005US20050054617 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
03/10/2005US20050054602 Oligonucleotides containing activated lymphocytes; antibody therapy; antiallergens; skin disorders
03/10/2005US20050054595 Genetic engineering; gene expression of target agent
03/10/2005US20050054594 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
03/10/2005US20050054593 New drug
03/10/2005US20050054580 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
03/10/2005US20050054575 Peptide agonists of prostate-specific antigen and uses therefor
03/10/2005US20050054567 Polypeptides; adjust concentration of stem cells
03/10/2005US20050054095 For treatment and/or prevention of inflammation and autoimmune disease; vaccines
03/10/2005US20050054074 Cell line comprising embryonated poultry cells and attenuated viral particles for use as tool in generation of vaccine for treatment and prevention of in fection by of influenza virus; immunotherapeutics
03/10/2005US20050054041 Kini-3 motor protein and methods for its use
03/10/2005US20050054036 Growth factor isoform
03/10/2005US20050054019 Human monoclonal antibody for use in the diagnosis prevention and treatment of cell proliferative disorders; immunotherapy; immunodiagnostics
03/10/2005US20050054018 Using cell cycle checkpoint activation modulators to prevent and treat cell proliferative disorders
03/10/2005US20050054016 Determination of bone-sialoprotein in bodily fluids for oncological problems
03/10/2005US20050054007 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof
03/10/2005US20050053943 Transmembrane protein for use in the diagnosis, detection, prevention and treatment of cell proliferative disorders; immunotherapy
03/10/2005US20050053935 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
03/10/2005US20050053611 Antibody directed enzyme prodrug therapy and a kit with antihumanseminal plasma protein single chain antibodies and prodrugs
03/10/2005US20050053609 Cancerous disease modifying antibodies
03/10/2005US20050053607 Proteins for treatment of cancer by administering antinucleolin
03/10/2005US20050053606 MUC1 extracellular domain and cancer treatment compositions and methods derived therefrom
03/10/2005US20050053601 Protein with amino acid sequences for central nervous systems in mammals
03/10/2005US20050053599 Antagonist for endothelial growth agents for treatment of edema and for kidney dialysis
03/10/2005US20050053581 Which effect p53 binding/inactivation; enhances efficacy of such viruses for treating cancer; liposomes
03/10/2005US20050053579 Conjugates of cytokines, chemokines, and interferons; genetic vaccines; for reducing tumor growth
03/10/2005CA2546482A1 Compositions and methods for delivery of biologically active agents
03/10/2005CA2539953A1 Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
03/10/2005CA2537170A1 Acid containing oxaliplatin formulations
03/10/2005CA2537161A1 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
03/10/2005CA2537115A1 Methods for the early diagnosis of ovarian cancer
03/10/2005CA2537099A1 Modulation of .beta.-catenin/tcf activated transcription
03/10/2005CA2537057A1 Cancer treatment with epothilones
03/10/2005CA2536911A1 Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor
03/10/2005CA2536788A1 Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
03/10/2005CA2536321A1 Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
03/10/2005CA2536174A1 N3-substituted imidazopyridine-derivatives as c-kit inhibitors
03/10/2005CA2536151A1 N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
03/10/2005CA2535896A1 N-substituted benzimidazolyl c-kit inhibitors
03/10/2005CA2535686A1 Proteasome inhibitors and methods of using the same
03/10/2005CA2531506A1 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
03/09/2005EP1512739A1 Chrondrocyte therapeutic delivery system
03/09/2005EP1512697A1 TNF Receptor action modulation
03/09/2005EP1512413A2 Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
03/09/2005EP1512399A1 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
03/09/2005EP1512016A1 Screening method and anti-tumor drug candidate obtained therefrom
03/09/2005EP1512014A2 Methods for the identification of all-antigens and their use for cancer therapy and transplantation
03/09/2005EP1512008A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
03/09/2005EP1511853A2 Regulation of novel human asparagine-hydroxylases
03/09/2005EP1511846A1 Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence
03/09/2005EP1511845A2 Immunostimulatory oligonucleotides and uses thereof
03/09/2005EP1511771A1 Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers
03/09/2005EP1511759A1 Modulators and inhibitors of fibroblast growth factor receptor 5-polypeptides and gene expression thereof.
03/09/2005EP1511757A1 New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
03/09/2005EP1511752A2 Camptothecins with a modified lactone ring
03/09/2005EP1511744A2 Bis-benzimidazoles and related compounds as potassium channel modulators
03/09/2005EP1511743A1 Pyrazole-derivatives as p38 kinase inhibitors
03/09/2005EP1511742A1 Kinase inhibitors
03/09/2005EP1511740A1 Phenyl-thiophene type vitamin d receptor modulators
03/09/2005EP1511737A1 Aryloximes
03/09/2005EP1511736A1 Therapeutic molecules and methods-1
03/09/2005EP1511734A2 Compounds, compositions, and methods
03/09/2005EP1511730A2 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
03/09/2005EP1511729A1 Histone deacetylase inhibitors based on alphachalcogenmethylcarbonyl compounds
03/09/2005EP1511725A1 24-SULFOXIMINE VITAMIN D sb 3 /sb COMPOUNDS
03/09/2005EP1511721A2 Guanidino phenylalanin compounds used as urokinase inhibitors
03/09/2005EP1511716A2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
03/09/2005EP1511713A2 Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
03/09/2005EP1511710A1 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease
03/09/2005EP1511519A1 Modified byrodin 1 with reduced immunogenicity
03/09/2005EP1511514A1 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
03/09/2005EP1511513A2 Immunogenic compositions comprising a xenogenic prostate protein p501s
03/09/2005EP1511511A2 Use of il-19, il-22 and il-24 to treat hematopoietic disorders
03/09/2005EP1511505A2 Novel therapies and methods of screening for therapeutic compounds
03/09/2005EP1511500A2 Combination of anti-muscarinic agents and non-glucocorticoid steroids
03/09/2005EP1511497A1 Treatment of post-menopausal complaints in breast cancer patients which comprises tibolone and a serm
03/09/2005EP1511493A1 Use of peroxovanadium compounds as tumour cell growth suppressor
03/09/2005EP1511488A2 Human adam-10 inhibitors
03/09/2005EP1511478A2 Triptolide derivatives for modulation of apoptosis and immunosuppression
03/09/2005EP1511477A1 Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
03/09/2005EP1511476A2 Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
03/09/2005EP1511475A1 A herbal molecule as potential anti-leukemic drug
03/09/2005EP1511473A2 Bis-aromatic alkanols
03/09/2005EP1303261B1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
03/09/2005EP1237916B1 Ing2, an iaps associated cell cycle protein, compositions and methods of use
03/09/2005EP1162959B1 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
03/09/2005EP1108026B1 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
03/09/2005EP1054680B1 Treatment of bladder cancer by mycobacterium phlei cell wall
03/09/2005EP0944645B1 INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME
03/09/2005EP0935471B1 Mononuclear phagocytes in therapeutic drug delivery
03/09/2005EP0842273B1 Receptor ligand vegf-c
03/09/2005EP0817627B1 Protein kinase c inhibitors
03/09/2005CN1592793A Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas
03/09/2005CN1592755A Anti-angiogenic peptides
03/09/2005CN1592752A Inhibitors of the E2F-1/cyclin interaction for cancer therapy
03/09/2005CN1592748A Separation of regioisomers of metal phthalocyanines
03/09/2005CN1592744A Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity
1 ... 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 ... 2211